SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors debate the impact of Warren Buffett's transition away from active leadership and the company's decision to maintain record cash reserves rather than deploying capital into the current market rally. Community discussion centers on frustration over stagnant performance compared to broader indices, with many investors actively questioning the future direction of the conglomerate under CEO Greg Abel.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as members of the community point to recent Google research papers highlighting the protocol's post-quantum cryptography features as a potential long-term catalyst. While some investors remain cautious due to historical price performance, others are actively discussing institutional adoption narratives and technical developments as reasons to continue building their positions.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending as the community reacts to the announced preliminary design for the Phase 3 clinical trial of its lead candidate, CAD-1005, for Heparin-Induced Thrombocytopenia. Investors are actively debating the company's long-term clinical prospects versus concerns regarding ongoing cash burn and the potential for future equity offerings.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is trending following a strong quarterly earnings report that featured an EPS beat and raised full-year guidance, driven by significant momentum in its platform and advertising business. Investors and community members are actively debating the stock's long-term valuation and potential for further institutional upgrades, as the company reaches a milestone of 100 million streaming households.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche (AVAX) is facing intense bearish sentiment and significant volatility, with community members expressing deep frustration over its weak performance compared to Bitcoin and other assets. While some traders view the current price drop as a long-term accumulation opportunity for RWA tokenization, others are actively panic-selling and calling for a broader crypto market exit amid fears of a deeper downturn.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as investors debate whether the stock is a legitimate play on the critical indium phosphide supply chain bottleneck for AI infrastructure or an overvalued Chinese-led pump-and-dump scheme. Community discussion is polarized, with some highlighting high institutional interest and potential for parabolic gains, while critics point to massive insider selling, negative earnings, and concerns over significant upcoming share dilution.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently trending as investors focus on the potential of its lead asset, soquelitinib, following positive analyst price target initiations and anticipation surrounding upcoming data readouts. The community remains deeply divided, with bulls highlighting the drug's oral delivery and unique mechanism as a buyout candidate, while bears point to the stock's recent volatility and the risks inherent in early-stage clinical trials.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh the stock's long-term growth potential against market volatility driven by regional geopolitical tensions and evolving natural gas supply constraints. The community is actively debating whether the current price represents a buying opportunity ahead of upcoming earnings or if it will continue to trade in a range bound by persistent rumors regarding regional stability.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is drawing significant community attention as it navigates a complex retail landscape, balancing news of its nationwide digital price tag rollout with mixed sentiment regarding its current valuation multiples. Investors are actively debating whether its status as a defensive 'safe haven' remains justified given rising operational pressures and ongoing insider activity.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending following its Q4 2025 earnings report, which highlighted strong IBSRELA revenue growth and increased 2026 operating expenses, dividing community opinion while insider buying and a new LPGA partnership add to the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viking Therapeutics Faces Timeline Risk But Upside Could Be Huge

Viking Therapeutics stock faces near-term pressure, but its GLP-1 pipeline and clinical timeline could deliver significant long-term upside...

Viking Therapeutics, Inc. $VKTX Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 37.1% in the fourth quarter, according to the company in its most recent disclosure...

VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

Viking Therapeutics posts a wider Q1 loss as R&D spend jumps on Phase III obesity drug work, while it advances VK2735 studies and preps oral late-stage study.

<ul class="summary-bullets"><li>Big Tech earnings delivered mixed signals, with rising AI capex plans raising concerns about near-term profitability.</li><li>Oil surged amid escalating tensions with Iran, the United States Oil Fund ETF (USO) has surged 128% this year.&nbsp;</li><li>Investors now turn to PCE inflation data and jobless claims for clues on the Fed’s next move.</li></ul>U.S. stock futures slipped in early trade on Thursday as investors digested the wave of Big Tech earnings and rising geopolitical tensions in the Middle East.&nbsp;Brent crude futures jumped nearly 7% to over $120 following reports that President Trump is reviewing military strike options against Iran to break a nuclear negotiation deadlock. Shares of the United States Oil Fund ETF (USO) have risen over 120% this year so far.&nbsp;As of 4:00 a.m. ET on Thursday: Dow futures were down 0.6%, Russell 2000 futures declined 0.3%, S&amp;P 500 futures were down 0.1%, while Nasdaq futures were flat with a positive bias.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has remained in ‘bullish’ territory, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has moved back to ‘bullish’ from ‘neutral’ a day ago, even as four of the largest tech firms are now projecting combined capex of up to $725 billion by 2026.Trending Stocks To WatchMeta (META)&nbsp;stock fell another 9% in early premarket trade on bloated 2026 capex forecast of up to $145 billion and missed user growth. The Zuckerberg-led company signaled that its massive AI investments may take years to yield a significant return.&nbsp;Intel Corp (INTC): Shares continued their upmove from last week’s blowout beat, with fresh boost coming from U.S. President Donald Trump. In addition, news reports suggest it is in conversation with custom chip talks with Apple and Google.&nbsp;Microsoft (MSFT) posted a solid cloud beat, which was offset by a Q4 revenue outlook that missed analyst estimates. Stock fell nearly 2% in early premarket trading on Thursday.Alphabet Inc (GOOGL):&nbsp;Stock rose 6% in early premarket trade, rallying on cloud strength and continued AI momentum.&nbsp;Amazon (AMZN): Stock rose 3% in early premarket trade following a first-quarter beat.Qualcomm (QCOM)&nbsp;shares surged nearly 13% in early premarket trade after announcing in its earnings call that it will soon ship data center chips to a major hyperscale cloud provider.&nbsp;Apple (AAPL)&nbsp;will report its second quarter earnings on Thursday after the bell, its first report since it announced that John Ternus will succeed Tim Cook as CEO.&nbsp;Nvidia (NVDA):&nbsp;Reports suggest that black-market crackdowns in China have doubled the price of B300 AI servers to $1 million each.&nbsp;Shares of&nbsp;Viking Therapeutics, Inc. (VKTX)&nbsp;were under mild pressure in premarket trading on Thursday after the drugmaker said that its newer obesity drug candidate beat Novo Nordisk’s comparable therapy in animal studies.Robinhood (HOOD): Stock took a knock on Wednesday after missing Q1 revenue and EPS estimates.&nbsp;In an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/robinhood-cfo-addresses-hood-stock-selloff-after-q1-earnings-miss/cZBAOTvReEi">exclusive interview</a> with Stocktwits, Robinhood CFO Shiv Verma said the earnings miss was driven by a surge in active traders on lower pricing tiers, not weak demand. He added that April is tracking equity and options volumes at the highest month of the year, and on pace to be the second-best month in company history.&nbsp;Intellia Therapeutics (NTLA): Cathie Wood’s ARK Invest added more shares on Wednesday, along with HOOD.Other tickers trending on Stocktwits&nbsp;at the time of writing included Akanda Corp (AKAN), Jaguar Health Inc (JAGX) and Rolls Royce (RYCEY).Other Catalysts To WatchOn the economic front, traders will be watching the release of the PCE Price Index, a critical inflation gauge, alongside Initial Jobless Claims and the Chicago PMI.&nbsp;On earnings radar, watch out for quarterly reports from Caterpillar Inc (CAT), Eli Lilly (LLY), Mastercard Inc Class A (MA), Royal Caribbean Group Ltd (RCL), and Merck &amp; Co (MRK), among others, before the bell. Apart from Appls, Riot Platforms (RIOT), iBio Inc (IBIO), Rivian Automotive (RIVN), and others, report after-market close today.Editors Note: This copy has been updated to correct an earlier error in which the Amazon CEO was incorrectly referenced under the Alphabet (Google) section. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Lower As Trump Reviews Iran Strike Option: Why META, INTC, GOOGL, AAPL, QCOM, VKTX Are Keeping Traders Engaged Today

Data from Stocktwits shows that despite volatility, retail traders stayed bullish on SPY and turned positive again on QQQ.

Nasdaq, S&P 500 Futures Slip Ahead Of PCE Data, Oil Jumps On Iran Strike Fears: Why META, INTC, GOOGL, AAPL, QCOM, VKTX Are In Focus

Equity

Data from Stocktwits shows that despite volatility, retail traders stayed bullish on SPY and turned positive again on QQQ.


<ul class="summary-bullets"><li>The company's obesity drug candidate VK3019 showed stronger early weight-loss signals than Novo Nordisk’s amylin therapy.</li><li>The company said enrollment has been completed across both Phase 3 Vanquish trials evaluating weekly injectable VK2735.</li><li>Viking plans to launch Phase 3 development of the oral VK2735 formulation in Q4.</li></ul>Shares of Viking Therapeutics, Inc. (VKTX) slipped 0.4% in premarket trading on Thursday even after the drugmaker said that its newer obesity drug candidate delivered stronger early weight-loss signals than Novo Nordisk’s comparable therapy in animal studies.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> is on track to post its second straight month of losses, sliding nearly 4% so far in April.&nbsp;<h2 class="st-heading-2">VK3019 Boosts Viking’s Challenge To Novo Nordisk&nbsp;</h2>Investor sentiment has largely turned on optimism toward VK3019, Viking’s obesity candidate targeting the amylin receptor, a mechanism increasingly viewed as complementary to GLP-1-based therapies.CEO Brian Lian said on the company’s recent earnings call that early testing suggested the compound compared favorably with Novo Nordisk’s amylin candidate: “When we looked at data in rodents, it seemed to be better than Cagrilintide.”He also noted stronger signals relative to Viking’s own lead obesity therapy in animal testing, saying, “When we looked in obese monkeys, it seemed to provide better weight loss than VK2735.”“it was very potent on the receptors, very good PK [pharmacokinetics] profile that would be amenable to weekly dosing, we think, and that marries up nicely with the 2735-PK profile.” The company recently filed an investigational new drug application for VK3019 and expects to begin Phase 1 testing this quarter.<h2 class="st-heading-2">Viking Eyes Combo Obesity Strategy</h2>Viking also confirmed early discussions around combination development linking VK3019 with VK2735, pointing to a broader multi-mechanism obesity platform strategy. Lian said that the amylin program may expand treatment flexibility for patients unable to tolerate GLP-1 therapies.“Nice opportunity with this mechanism to potentially target people who are a little lower BMI… or people who maybe can’t tolerate the GLP-1 and want to try something different,” Lian added.<h2 class="st-heading-2">Phase 3 Momentum Builds For Lead Candidate&nbsp;</h2>While VK3019 drew attention for its early signals, Viking’s primary focus still remains VK2735, its dual GLP-1 and GIP receptor agonist being developed in both injectable and oral forms. The company said that enrollment has now been completed across both Phase 3 Vanquish trials evaluating weekly injectable VK2735 in adults with obesity and those with obesity plus type 2 diabetes.Alongside the injectable program, Viking is preparing to advance its oral VK2735 tablet formulation into Phase 3 development later this year following encouraging mid-stage trial results. The company said, “Every patient’s weight loss journey is unique, and we consistently hear from health care providers about the need for flexible treatment and administration options.”The company expects to initiate the Phase 3 oral program in the fourth quarter.<h2 class="st-heading-2">VKTX Q1 Review</h2>Viking reported a first-quarter net loss of $158.3 million, or $1.37 per share, wider than the consensus estimate of a $0.91 per-share loss and more than triple the $45.6 million, or $0.41 per share, loss recorded a year ago.&nbsp;The increase was largely driven by a sharp rise in research and development spending to advance its Phase 3 obesity trials and manufacturing activities. Research and development expenses rose to $150 million during the quarter from $41 million a year earlier.Despite the higher spending levels, the company ended the quarter with approximately $603 million in cash, cash equivalents and short-term investments, compared with $706 million at the end of 2025.<h2 class="st-heading-2">How Do Retail Traders View VKTX?</h2>On Stocktwits, retail sentiment for VKTX jumped to ‘bullish’ from ‘bearish’ levels a day ago amid nearly a 200% jump in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/vktx_ss_png_a09757779d.webp" alt="vktx ss.png" width="975" height="148"><figcaption>VKTX sentiment and message volume as of April 30 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/symbol/VKTX">said</a>, “Viking therapeutics is synonymous with the word goldmine. I can't wait to see this cross the finish line. It's going to be a glorious day!”<stembedurl>https://stocktwits.com/symbol/VKTX</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/crypto_biotech/message/651823565">said</a> VKTX was “BASICALLY Best in Class in everything.”<stembedurl>https://stocktwits.com/crypto_biotech/message/651823565</stembedurl>VKTX stock has risen 12% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uso-etf-surges-trump-iran-conflict-us-oil-supplier-last-resort/cZBMGwGReEz">USO ETF Eyes Record Year As Trump Weighs Iran Escalation — US Seen As Oil Market’s ‘Supplier Of Last Resort’&nbsp;</a>

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Stock Slips Premarket: A Surprise Weight Loss Drug Beats Novo Nordisk In Early Animal Tests 

Viking confirmed early combination-development discussions between VK3019 and VK2735.

A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival

Viking Therapeutics Q1 Earnings Call Highlights

Viking Therapeutics (NASDAQ:VKTX) reported first-quarter 2026 financial results and outlined progress across its obesity pipeline during an earnings call held April 29, 2026. Management emphasized...

<ul class="summary-bullets"><li>The company posted a Q1 net loss of $158.3 million, or $1.37 per share — more than triple the $45.6 million loss reported in the year-ago period.</li><li>Viking ended the quarter with $603 million in cash, cash equivalents, and short-term investments, down from $706 million at year-end 2025.</li><li>The company also confirmed plans to launch a late-stage trial of the oral tablet formulation of VK2735 in the fourth quarter of 2026.</li></ul> Shares of Viking Therapeutics (VKTX) dropped 2% after hours on Wednesday after the clinical-stage biotech reported first-quarter results that showed a sharp increase in cash burn tied to the rapid advancement of its late-stage obesity and metabolic disease pipeline.The company posted a net loss of $158.3 million, or $1.37 per share, for the quarter ended March 31, 2026 — more than triple the $45.6 million loss ($0.41 per share) reported in the year-ago period. Research and development expenses jumped to $150.2 million from $41.4 million a year earlier, driven by clinical trial costs, manufacturing scale-up, and personnel expenses related to its lead programs.Viking ended the quarter with $603 million in cash, cash equivalents, and short-term investments, down from $706 million at year-end 2025 but still providing a substantial runway for its clinical programs.<h2 class="st-heading-2">Viking’s Pipeline Efforts</h2>Viking is currently trying to advance its flagship obesity candidate VK2735, a dual GLP-1/GIP receptor agonist available in both subcutaneous and oral formulations. Both late-stage trials of the subcutaneous version are now fully enrolled ahead of schedule. While one of the studies enrolled more than 4,500 patients, the other enrolled approximately 1,000 patients.The company also confirmed plans to launch a late-stage trial of the oral tablet formulation of VK2735 in the fourth quarter of 2026, following positive feedback from an end-of-Phase 2 meeting with the FDA.An ongoing Phase 1 maintenance dosing study for VK2735 — evaluating various regimens after initial weight loss — completed enrollment in January, with data expected in the third quarter of 2026.On the earlier-stage front, Viking filed an application seeking to commence clinical trials for its novel amylin agonist VK3019 in the first quarter. Viking expects to initiate an early-stage trial in the second quarter of 2026. Amylin agonists are a class of medication that mimic the hormone amylin, which is co-secreted with insulin by pancreatic cells to manage glucose levels and appetite. The candidate is being developed as a potential option for patients who may not tolerate GLP-1-based therapies.Viking CEO Brian Lian said in March that the company will have four late-stage trials by the end of 2026.“2025 was a big year for us. 2026 is gonna be a big year as well,” Lian said at the Leerink Global Healthcare Conference.The CEO also expressed optimism that weight loss for the subcutaneous VK2735 trials will probably be a “little better than a GLP-1 monoagonist” though he couldn't predict its impact in comparison to other "polyagonists." While Novo Nordisk’s popular weight loss drug Wegovy is a single-agonist drug, Eli Lilly and Company’s Zepbound is a dual agonist.<h2 class="st-heading-2">How Did VKTX Retail Traders React?</h2>On Stocktwits, retail sentiment around VKTX jumped from 'bearish' to 'bullish' territory over the past 24 hours, while message volume increased from 'low' to 'normal' levels.A Stocktwits user expressed optimism for the company’s obesity pipeline.<stembedurl>https://www.stocktwits.com/Robbullishious/message/651824368</stembedurl>Another highlighted the size of the obesity market, while drawing a parallel between VKTX’s lead candidate and Eli Lilly’s development pipeline.<stembedurl>https://www.stocktwits.com/durocali/message/651823807</stembedurl><a href="https://stocktwits.com/symbol/VKTX">VKTX</a> has gained 12% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/pypl-stock-rises-after-considering-splitting-off-venmo-as-standalone-segment-report/cZBAXVsReES">PYPL Stock Rises After Considering Splitting Off Venmo As Standalone Segment: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

VKTX Shares Drop After Hours On Larger Q1 Losses But Retail Eyes The Launch Of Its Obesity Pipeline

Viking is currently trying to advance its flagship obesity candidate VK2735, available in both subcutaneous and oral formulations.

Viking Therapeutics (NASDAQ:VKTX) Releases Earnings Results, Misses Estimates By $0.36 EPS

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($1.37) earnings per share for the quarter, missing the...

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update PR...

Can Oral Ozempic and Label Expansions Revive NVO's Near-Term Growth?

Novo Nordisk bets on oral Ozempic launch and pediatric label expansions to counter slowing demand, pricing pressure and rising competition in the GLP-1 market.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VKTX News

VKTXViking Therapeutics Inc